{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Rifampin+%26+midazolam", "query": { "intervention": "Rifampin & midazolam" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-28T22:20:15.989Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01218620", "title": "Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm" ], "interventions": [ { "name": "Gamma-Secretase Inhibitor RO4929097", "type": "DRUG" }, { "name": "Ketoconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Midazolam Hydrochloride", "type": "DRUG" }, { "name": "Omeprazole", "type": "DRUG" }, { "name": "Tolbutamide", "type": "DRUG" }, { "name": "Dextromethorphan Hydrobromide", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2010-09", "completion_date": "2014-12", "has_results": false, "last_update_posted_date": "2014-12-23", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 1, "location_summary": "Madison, Wisconsin", "locations": [ { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT01218620" }, { "nct_id": "NCT02085967", "title": "A 2-Part Study to Assess Potential Metabolism-Based Drug-Drug Interactions of E2006 When Coadministered With Itraconazole, Rifampin, Midazolam, or Bupropion", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Subjects" ], "interventions": [ { "name": "rifampin 600 mg", "type": "DRUG" }, { "name": "itraconazole 200 mg", "type": "DRUG" }, { "name": "midazolam 2 mg with bupropion 75 mg", "type": "DRUG" }, { "name": "E2006", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 106, "start_date": "2014-02", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2015-11-03", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 1, "location_summary": "Austin, Texas", "locations": [ { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02085967" }, { "nct_id": "NCT01026415", "title": "Clinical Pharmacology Study of Brentuximab Vedotin (SGN-35)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Carcinomas", "Disease, Hodgkin", "Lymphoma, Large-Cell, Anaplastic", "Lymphoma, Non-Hodgkin", "Neoplasms" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "rifampin", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "ketoconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 73, "start_date": "2009-12", "completion_date": "2012-05", "has_results": false, "last_update_posted_date": "2014-12-18", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 6, "location_summary": "Duarte, California • Denver, Colorado • Indianapolis, Indiana + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01026415" }, { "nct_id": "NCT06004947", "title": "A Study in Healthy Volunteers to Evaluate the Drug-Drug Interaction Potential of CCX168 With Concomitant Medications", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis" ], "interventions": [ { "name": "CCX168", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Celecoxib", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Amgen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 32, "start_date": "2016-01-14", "completion_date": "2016-06-10", "has_results": false, "last_update_posted_date": "2023-08-22", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06004947" }, { "nct_id": "NCT01162486", "title": "Pharmacokinetics, Safety and Tolerability of Escalating Rifapentine Doses in Healthy Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Tuberculosis", "Tuberculosis, Pulmonary" ], "interventions": [ { "name": "Rifampin & midazolam", "type": "DRUG" }, { "name": "rifapentine and midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 37, "start_date": "2010-04", "completion_date": "2011-03", "has_results": true, "last_update_posted_date": "2019-05-07", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01162486" }, { "nct_id": "NCT03311841", "title": "Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin in Participants With Renal Insufficiency in the Presence and Absence of Rifampin (MK-0000-386)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Insufficiency" ], "interventions": [ { "name": "Midazolam oral solution", "type": "DRUG" }, { "name": "Dabigatran and pitavastatin oral solution", "type": "DRUG" }, { "name": "Atorvastatin and rosuvastatin oral solution", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "78 Years", "sex": "ALL", "summary": "18 Years to 78 Years" }, "enrollment_count": 32, "start_date": "2018-03-01", "completion_date": "2018-08-02", "has_results": true, "last_update_posted_date": "2020-01-09", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 2, "location_summary": "Hialeah, Florida • Orlando, Florida", "locations": [ { "city": "Hialeah", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03311841" }, { "nct_id": "NCT04493931", "title": "Drug-drug Interaction Study of Gepotidacin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Infections, Bacterial" ], "interventions": [ { "name": "Gepotidacin", "type": "DRUG" }, { "name": "Cimetidine", "type": "DRUG" }, { "name": "Rifampicin", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" }, { "name": "Placebo matching to gepotidacin", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 64, "start_date": "2020-08-14", "completion_date": "2020-12-21", "has_results": true, "last_update_posted_date": "2022-03-04", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 1, "location_summary": "Las Vegas, Nevada", "locations": [ { "city": "Las Vegas", "state": "Nevada" } ], "official_url": "https://clinicaltrials.gov/study/NCT04493931" }, { "nct_id": "NCT00621309", "title": "Sulforaphane as an Antagonist to Human PXR-mediated Drug-drug Interactions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adverse Drug Interactions" ], "interventions": [ { "name": "Rifampicin", "type": "DRUG" }, { "name": "sulforaphane plus rifampicin", "type": "DIETARY_SUPPLEMENT" }, { "name": "sulforaphane alone", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "40 Years", "sex": "ALL", "summary": "18 Years to 40 Years" }, "enrollment_count": 29, "start_date": "2008-03", "completion_date": "2010-09", "has_results": true, "last_update_posted_date": "2019-09-06", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 2, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00621309" }, { "nct_id": "NCT04142762", "title": "A Study to Assess CYP3A4 Modulator, Oral Contraceptive, and pH Modifier Drug Interactions for ABI-H2158 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis B" ], "interventions": [ { "name": "ABI-H2158", "type": "DRUG" }, { "name": "Itraconazole", "type": "DRUG" }, { "name": "Rifampin", "type": "DRUG" }, { "name": "Midazolam", "type": "DRUG" }, { "name": "Ethinyl Estradiol / Levonorgestrel", "type": "DRUG" }, { "name": "Esomeprazole", "type": "DRUG" }, { "name": "Placebo matching oral contraceptive", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Assembly Biosciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 80, "start_date": "2019-10-18", "completion_date": "2020-01-29", "has_results": false, "last_update_posted_date": "2020-03-04", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 1, "location_summary": "Tempe, Arizona", "locations": [ { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT04142762" }, { "nct_id": "NCT03723395", "title": "A Drug-Drug Interaction Study in Healthy Volunteers of the Effects of Tucatinib", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Drug-drug Interaction" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "itraconazole", "type": "DRUG" }, { "name": "rifampin", "type": "DRUG" }, { "name": "gemfibrozil", "type": "DRUG" }, { "name": "repaglinide", "type": "DRUG" }, { "name": "tolbutamide", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" }, { "name": "digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 116, "start_date": "2018-09-17", "completion_date": "2018-12-28", "has_results": false, "last_update_posted_date": "2019-12-18", "last_synced_at": "2026-09-28T22:20:15.989Z", "location_count": 2, "location_summary": "Daytona Beach, Florida • Dallas, Texas", "locations": [ { "city": "Daytona Beach", "state": "Florida" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03723395" } ] }